Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 11,500 shareholders.
For further information, please contact:
Guillaume van Renterghem
LifeSci Advisors, Investor Relations
Email: ir@alligatorbioscience.com